This submission aims to advance the debate regarding how best to achieve the objectives of the CBD. Previous debate on the issue of access and benefit sharing (hereafter ABS) has at times been marked by a polarisation of standpoints and a lack of understanding of the practical complexities, subtleties and implications of the issue. It is important that policy makers and stakeholders involved in the debate are fully aware of what is actually at stake for various stakeholders and indeed for society in general.
This document will provide an overview of the issues surrounding the use of genetic resources by the research-based pharmaceutical industry and will be divided into three main sections:
(i) Understanding the business case for biodiversity
(ii) Case studies: successful and responsible business practice
(iii) Moving the debate forward - recommendations and conclusions
By: ￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼European Federation of Pharmaceutical Industries and Associations